Product Name:

NebuPeptide™ Insulin degludec/Liraglutide (Peptide Reference)

Catalog Number:

NBS-233778

Description:

NebuPeptide™ Insulin degludec/Liraglutide (Peptide Reference)(CAT#NBS-233778) is synthesized in accordance with the Insulin degludec/Liraglutide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Vosoritide reference peptide ranging from milligrams to kilograms.

Peptide Name:

Insulin degludec/Liraglutide (利拉鲁肽)

Background:

Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise. It contains insulin degludec and liraglutide. Insulin degludec is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time. Liraglutide belongs to the class of diabetes medicines known as GLP-1 receptor agonists. It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

Alias:

N/A

CAS Number:

N/A

Formula:

N/A

Molecular Weight:

N/A

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.